VOR Stock: Price, Earnings History and SEC Filings
Vor Biopharma Inc. (VOR) last traded at $19.68, down 5.88% on the latest session and up 3.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.80 against an analyst estimate of $-0.69, a miss of 15.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VOR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.80 | $-0.69 | -15.94% |
| Mar 2026 | May 13, 2026 | $-0.73 | $-0.75 | +2.67% |
VOR beat the analyst EPS estimate in 1 of its last 2 reported quarters. Source: Nasdaq.
VOR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$696M | -$144M | – | $-70.50 |
| 2024 | – | -$117M | -$100M | – | $-34.03 |
| 2023 | – | -$118M | -$101M | – | $-1.75 |
| 2022 | – | -$92M | -$94M | – | $-2.33 |
| 2021 | – | -$69M | -$73M | – | $-2.10 |
| 2020 | – | -$43M | -$40M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for VOR
- 424B5 · Oct 30, 2026
- 10-Q · Oct 30, 2026
- 10-Q · Aug 11, 2026
- 8-K · Jul 7, 2026Officer or director change, Financial statements and exhibits
- 8-K · Jun 12, 2026Shareholder vote, Financial statements and exhibits
- 8-K · Jun 8, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 13, 2026
- S-3 · Apr 27, 2026
- DEF 14A · Apr 27, 2026
- 10-K · Mar 30, 2026
Insider filing activity
VOR insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
VOR news
- Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateOct 30, 2026 · finance.yahoo.com
- Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA NephropathyOct 22, 2026 · finance.yahoo.com
About Vor Biopharma Inc.
Vor Biopharma Inc. (VOR) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). Its fiscal year ends in December.